MENU

Fox Chase Cancer Center News

June 15, 2021

Next-Generation Sequencing in Patient Case Finds Novel Fusion Gene in Pleomorphic Adenoma

PHILADELPHIA (June 9, 2021)—Researchers at Fox Chase Cancer Center investigating psychological distress in patients with metastatic cancer enrolling in phase 1 clinical trials found that although physical stressors did not strongly relate to patients’ overall level of distress, emotional, family, and practical stressors did.

June 9, 2021

COVID-19 Vaccination Caused Increased FDG Uptake During PET Scan in Patient Case

PHILADELPHIA (June 9, 2021)—A 70-year-old woman with Hodgkin Lymphoma being treated at Fox Chase Cancer Center had increased FDG uptake in her lymph nodes two days after receiving a COVID-19 vaccination. FDG is short for fluorodeoxyglucose, a radiolabeled sugar used during positron emission tomography (PET) scans.

June 9, 2021

Researchers Show Why Statins Can Be Used to Treat Medulloblastoma Without Side Effects

PHILADELPHIA (June 9, 2021)—There’s growing evidence that statins can offer an effective treatment for medulloblastoma, a childhood brain cancer, without the severe side effects of other chemotherapy drugs. Now a new study by researchers at Fox Chase Cancer Center explains why.

June 9, 2021

Family, Personal Stressors Cause More Distress Than Pain and Other Symptoms in Phase 1 Clinical Trial Patients

PHILADELPHIA (June 9, 2021)—Researchers at Fox Chase Cancer Center investigating psychological distress in patients with metastatic cancer enrolling in phase 1 clinical trials found that although physical stressors did not strongly relate to patients’ overall level of distress, emotional, family, and practical stressors did.

June 8, 2021

New Prognostic Model More Accurately Predicts Kidney Cancer Recurrence and Patient Survival

PHILADELPHIA (June 8, 2021)—Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with kidney cancer more accurately than other models currently in use.

June 4, 2021

No Survival Difference for Frontline Combination Regimens in Real World Intermediate-Risk and Poor-Risk Clear Cell RCC

PHILADELPHIA (June 4, 2021) – A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they are treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab.

June 4, 2021

Fox Chase Researchers Find Racial Disparities in Prostate Cancer Surgery Rates During COVID-19

PHILADELPHIA (June 4, 2021)—The likelihood of prostate cancer surgery for patients presenting for treatment across Pennsylvania declined among Black patients, but not white patients, during the initial wave of the COVID-19 pandemic, according to new research from Fox Chase Cancer Center.

June 3, 2021

Research Finds Need to Train Oncologists to Better Communicate Information on Genetic Profiling of Tumors

PHILADELPHIA (June 3, 2021)—Researchers from Fox Chase Cancer Center have presented new data showing that oncologists feel underprepared to communicate the results of tumor genetic profiling (TGP) to their patients, particularly to African American patients who have more mistrust around healthcare and particularly around genetic information and testing.

Pages

Connect with Fox Chase